🇺🇸 FDA
Pipeline program

INAVOLISIB, DOCETAXEL, INAVOLISIB, ENZALUTAMIDE, ENZALUTAMIDE, ABIRATERONE

CO45813

Phase 2 small_molecule active

Quick answer

INAVOLISIB, DOCETAXEL, INAVOLISIB, ENZALUTAMIDE, ENZALUTAMIDE, ABIRATERONE for Metastatic Castration-Resistant Prostate Cancer is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Metastatic Castration-Resistant Prostate Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials